bioAffinity Technologies (BIAF) Expected to Release Quarterly Earnings on Wednesday

Posted by Stanley Muller on Nov 11th, 2026

bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 18th. Analysts expect the company to announce earnings of ($31.50) per share and revenue of $1.91 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 7:00 AM ET.

bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported ($5.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($31.50) by $25.61. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1.91 million. bioAffinity Technologies had a negative net margin of 278.90% and a negative return on equity of 278.67%.

bioAffinity Technologies Stock Up 5.8%

Shares of NASDAQ BIAF opened at $2.39 on Wednesday. The company’s 50 day moving average price is $5.80 and its 200-day moving average price is $18.51. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.41 and a current ratio of 1.44. bioAffinity Technologies has a 52-week low of $2.25 and a 52-week high of $80.70. The company has a market capitalization of $1.44 million, a P/E ratio of -0.05 and a beta of -1.03.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of bioAffinity Technologies from a “sell” rating to a “hold” rating in a research report on Monday, August 10th. Weiss Ratings restated a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Friday, October 16th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, bioAffinity Technologies currently has a consensus rating of “Sell”.

View Our Latest Report on BIAF

bioAffinity Technologies Company Profile

(Get Free Report)

bioAffinity Technologies, Inc. is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other serious diseases. The company’s platform uses porphyrin-based compounds designed to selectively identify or target abnormal cells, with the goal of supporting earlier disease detection and more precise treatment. Its lead diagnostic product, CyPath Lung, is an investigational, noninvasive urine test intended to aid in the detection of lung cancer. The test uses an inhaled porphyrin compound that can bind to cancer cells in the lungs; the resulting material is collected in urine and analyzed using laboratory methods.